The aim of this study was to prospectively validate the Bova score in different settings from the original derivation cohort.

Thirty-day serious adverse events (SAE) were reported based on the original derivation study and standardised outcome reporting for syncope.

Two validation cohorts were used: follow-up from the original derivation cohort (cohort 1) and an independent Korean PVC registry (cohort 2).